Genes and proteins of brachyspira hyodysenteriae and use thereof

FIELD: chemistry.

SUBSTANCE: invention describes novel polynucleotide and amino acid sequences of Brachyspira hyodysenteriae, which can be used to diagnose diseases in animals, caused by B. hyodysenteriae, to treat or prevent diseases associated with infection with B. hyodysenteriae. The invention describes a cell containing a plasmid containing a polynucleotide, for treating and preventing a disease associated with infection of an animal with B. Hyodysenteriae. The invention describes immunogenic and vaccine compositions for generating immune response in an animal, which contain a polypeptide, a polynucleotide, a cell or a plasmid for treating or preventing infection of animals by B. hyodysenteriae, as well as sets of instruments for diagnosis which contain a monoclonal antibody, capable of biding the disclosed polypeptide or a polypeptide or polynucleotide. The invention enables to successfully diagnose diseases caused by B. hyodysenteriae, prevent or treat animals infected with B. hyodysenteriae. The sequences described herein can be used for diagnosis and therapeutic and/or preventive treatment of animals from diseases caused by other types of Brachyspira, including B. intermedia, B. suantatina, B. alvinipulli, B. aalborgi, B. innocens, B. murdochii and B. pilosicoli.

EFFECT: high efficiency of using the composition.

39 cl, 4 tbl

 

The text descriptions are given in facsimile form.

1. The polypeptide comprising a sequence which is selected from the group consisting of the sequences SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 and 66, for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae.

2. Polynucleotide comprising a sequence that encodes a polypeptide according to claim 1, for treating or preventing diseases associated with infection with Brachyspira hyodysenteriae.

3. Polynucleotide according to claim 2, comprising a sequence which is selected from the group consisting of the following sequences SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63 and 65.

4. A plasmid comprising polynucleotide according to claim 2 or 3, for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae.

5. Plasmid according to claim 4, representing the expression vector.

6. The cell containing the plasmid according to claim 4, for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae.

7. The cell containing the plasmid according to claim 5, where the plasmid includes polynucleotide according to claim 3, for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae.

8. Immunogenic composition comprising the cell according to claim 6 for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae.

9. A protein comprising a sequence that is at least 70% homologous to a polypeptide according to claim 1, for treating or preventing diseases associated with infection with Brachyspira hyodysenteriae.

10. The protein according to claim 9, which is at least 80% homologous to a polypeptide according to claim 1.

11. the trees of claim 10, which at least 90% homologous to a polypeptide according to claim 1.

12. Immunogenic composition comprising a protein according to claim 11, for treating or preventing diseases associated with infection with Brachyspira hyodysenteriae.

13. Immunogenic composition comprising the polypeptide according to claim 1, for treating or preventing diseases associated with infection with Brachyspira hyodysenteriae.

14. Immunogenic composition comprising a plasmid according to claim 5, for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae.

15. The composition of vaccines for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae, comprising the polypeptide according to claim 1.

16. The composition of vaccines for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae, including polynucleotide according to claim 3.

17. The composition of vaccines for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae, including cell according to claim 6, containing a plasmid comprising polynucleotide according to claim 3.

18. The DNA molecule, comprising a sequence that is at least 70% identical to polynucleotide according to claim 3.

19. The DNA molecule according p that at least 80% identical to polynucleotide according to claim 3.

20. The DNA molecule according to claim 19, which is at least 90% identical to polynucleotide according to claim 3.

21. Plasmid comprising Poliny eated on any of PP-20, for the treatment or prevention of diseases associated with infection with Brachyspira hyodysenteriae.

22. Monoclonal antibody, which binds to the polypeptide according to claim 1.

23. A kit for diagnosing the presence of Brachyspira hyodysenteriae in an animal, comprising the monoclonal antibody according to item 22.

24. A kit for diagnosing the presence of Brachyspira hyodysenteriae in an animal, comprising the polypeptide according to claim 1.

25. A kit for diagnosing the presence of Brachyspira hyodysenteriae in an animal, including polynucleotide according to claim 3.

26. The method of generating an immune response in Brachyspira hyodysenteriae in an animal, comprising the introduction of a specified animal the immunogenic composition according to item 12.

27. The method of generating an immune response in Brachyspira hyodysenteriae in an animal, comprising the introduction of a specified animal the immunogenic composition according to item 13.

28. The method of generating an immune response in Brachyspira hyodysenteriae in an animal, comprising the introduction of a specified animal the immunogenic composition of 14.

29. The method of generating an immune response in Brachyspira hyodysenteriae in an animal, comprising the introduction of a specified animal the immunogenic composition of claim 8.

30. A method of treating or preventing diseases caused by Brachyspira hyodysenteriae, the animal in need of such treatment, comprising the introduction of a specified animal a therapeutically effective amount of the vaccine composition according to item 16.

31. A method of treating or preventing diseases caused by Brachyspira hyodysenteriae, the animal in need of such treatment, comprising the introduction of a specified animal a therapeutically effective amount of the composition of the vaccine by 17.

32. A method of treating or preventing diseases caused by Brachyspira hyodysenteriae, the animal in need of such treatment, comprising the introduction of a specified animal a therapeutically effective amount of the vaccine composition according to item 15.

33. The use of a protein according to claim 11 for obtaining a medicinal product for the generation of the immune response against Brachyspira hyodysenteriae in an animal.

34. The use of the polypeptide according to claim 1 for obtaining a medicinal product for the generation of the immune response against Brachyspira hyodysenteriae in an animal.

35. The use of a plasmid according to claim 5, including polynucleotide according to claim 3, to obtain drugs for the generation of the immune response against Brachyspira hyodysenteriae in an animal.

36. The use of cells according to claim 6 for obtaining a medicinal product for the generation of the immune response against Brachyspira hyodysenteriae in an animal.

37. The use of the expression vector according to claim 5, including polynucleotide according to claim 3, to obtain drugs for treating or preventing diseases caused by Brachyspira hyodysenteriae, the animal in need of such treatment.

38. The use of cells according to claim 6, containing plasma is, including polynucleotide according to claim 3, to obtain drugs for treating or preventing diseases caused by Brachyspira hyodysenteriae, the animal in need of such treatment.

39. The use of the polypeptide according to claim 1 for obtaining a medicinal product for treating or preventing diseases caused by Brachyspira hyodysenteriae, the animal in need of such treatment.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to versions of glucoamylase with altered properties and to methods of glucoamylase versions application.

EFFECT: reduced formation of condensation products and increase of glucose output during starch conversion.

22 cl, 2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: recombinant technique is used to obtain a fused polypeptide with activity of interleukin-7, containing a modified human IL-7 molecule in which the T-cell epitope is modified to reduce T-cell response against IL-7, and the Fc part of an immunoglobulin molecule which is fused through its C-end with the N-end of said modified IL-7 molecule. The obtained polypeptide is used in a pharmaceutical composition to stimulate immune response in a patient.

EFFECT: invention enables to obtain a polypeptide with interleukin-7 activity, having low immunising capacity.

8 cl, 43 dwg, 14 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: there are offered versions of antibodies specific to CD22 epitope located from amino acid 22 to amino acid 240 CD22. There are disclosed: a coding polynucleotide, an expression vector, a based host cell and a method of producing an antibody with the use of the cell. There are described versions of a method of CD22 detection on the basis of the antibodies. There are disclosed versions of the CD22 immunoconjugate and based pharmaceutical compositions for treating disturbed B-cell proliferation, and also versions of a method of treating with the use of the pharmaceutical composition. There is disclosed a method of B-cell proliferation inhibition on a basis the immunoconjugate. There are described versions of an engineered cystein-substituted antibody specific to CD22 with one or more free cysteines of thiol reactance within the range 0.6 to 1.0. There are disclosed versions of the "antibody-drug" conjugate, the immunoconjugate and pharmaceutical formulaitons for treating disturbed B-cell proliferation. There are also described a method for protein CD22 detection in a sample on the basis of the immunoconjugate, a method for B-cell detection and a method of treating a malignant tumour on the basis of the "antibody-drug" conjugate. There are disclosed: a product for treating disturbed B-cell proliferation on the basis of the pharmaceutical formulation and a method of producing the "antibody-drug" conjugate.

EFFECT: use of the invention provides new specific CD22 antibodies and the based drugs of acceptable therapeutic efficacy with lower toxicity that can find application in therapy of tumours.

227 cl, 25 dwg, 16 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: method involves cultivation of an obligate methanol-assimilating bacterium Methylophilus methylotrophus or Methylobacillus glycogens in a fluid medium with the bacterium secreting an end protein from a bacterial cell where said bacterium has a DNA structure containing a promoter sequence functioning in the methanol-assimilating bacterium, a nucleotide sequence coding a polypeptide containing a signal sequence which functions in the methanol-assimilating bacterium, and a sequence of the end protein functionally connected with the promoter sequence.

EFFECT: method allows producing the protein effectively by means of extracellular secretion, difficult-to-produce by means of secretory production with application of Escherichia coli bacteria.

5 cl, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to recombinant plasmid DNA pER-Hir coding a hybrid protein capable to autocatalytic breakdown to form [Leul, Thr2]-63-desulphatohirudin, to Escherichia coli to an ER2566/pER-Hir strain - a producer of said protein and a method for producing genetically engineered [Leu 1, Thr2]-63-desulphatohirudin. The presented recombinant plasmid DNA consists of the SapI/BamHI fragment of DNA plasmid pTWIN-1 containing a promoter and a terminator of T7-RNA-polymerase transcription, an amplifier of phages T7 gene 10 translation, β-laktamase (Ap) gene, modified mini-intein Ssp DnaB gene, with an integrated sequence of a chitin-binding domain, and the SapI/BamHI-fragment of DNA containing a sequence of a gene of recombinant [Leul, Thr2]-63-desulphatohirudin-1 containing β-laktamase (Ap) gene as a genetic marker, and unique recognition sites of restriction endonucleases located at the following distance to the left from the site BamHI: Nrul - 186 base pairs, Ndel - 594 base pairs, Xbal - 882 base pairs, EcoRV - 2913 base pairs, Hpal - 2966 base pairs.

EFFECT: inventions allow producing said compound which is used as a drug applied to prevent blood hypercoagulation.

3 cl, 1 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: vector carries an additional transcription unit containing a foreign gene functionally coupled with an overlying starting sequence of a virus gene (GS) of Mononegavirales order and an underlaying end sequence of a virus gene (GE) of Mononegavirales order; between the GS sequence and an initiator codon of the foreign gene and between a stop sign of the foreign gene and the GE sequence there are respectively 3'-noncoding area and 5'-noncoding area (a genome sense chain) of the virus gene of Mononegavirales order.

EFFECT: higher expression level of the protein coded by the foreign gene.

22 cl, 9 dwg, 6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: what is offered is a DNA molecule recovered from Bifidobacterium bifidum, with a sequence presented in the description, and its degenerate derivative coding β-galactosidase. Also, what is presented is a p-galactosidase enzyme having a sequence presented in the description. What is offered is an expression vector containing said DNA, and a bacterial host cell containing said vector. What is offered is application of the enzyme or the host cell for preparing a mixture of oligosaccharides which can be used for preparation of foodstuff, forages for animals and medicines. What is described is a method for producing the enzyme involving cultivation of said host cell in an appropriate culture medium under conditions supposing expression of said enzyme and recovery of the prepared enzyme from the culture.

EFFECT: invention allows transforming lactose into a mixture of oligosaccharides.

12 cl, 5 dwg, 3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: claimed invention can be used in microbiligical industry for obtaining recombinant strains of fungi Acremonium chrysogenum - superproducents of cephalosporin C. Plasmid contains expression cassette, which consists of promoter of Aspergillus nidulans glyceraldehide phosphate dehydrogenase gene, terminator of Saccharomyces cerevisiae phosphoglycerate kinase gene, separated by polylinker site. As dominant selective marker it contains gene of Escherichia coli hygromycin-B phosphotransferase under control of promoter trpC Aspergillus nidulans, which determines stability to hygromycin of recombinant strains of mycelial fungi, transformed by plasmid pZEN16 and its derivatives.

EFFECT: claimed invention makes it possible to receive unique vector for agrobacterial transformation of Acremonium chrysogenum, which makes it possible to realise constitutive expression of target genes, responsible for biosynthesis and transport of cephalosporin C.

1 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to isolated nucleic acid, encoding protein with activity of fluorescent biosensor for hydrogen peroxide detection, expression vector, containing said nucleic acid, cell of E.coli, producing protein, encoded by said nucleic acid, and isolated protein, with activity of fluorescent biosensor for hydrogen peroxide detection. Isolated protein, with activity of fluorescent biosensor for hydrogen peroxide detection, has amino acid sequence, presented in form SEQ ID NO: 2. Expression vector contains nucleic acid, encoding protein with activity of fluorescent biosensor for hydrogen peroxide detection, under control of regulatory elements, necessary for expression of nucleic acid in host cell. Cell of E.coli is modifies due to introduction into it of nucleic acid, encoding protein with activity of fluorescent biosensor for hydrogen peroxide detection, functionally connected with regulatory sequence.

EFFECT: claimed invention is applied for detection of hydrogen peroxide inside live cells.

4 cl, 3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: polypeptide, which is used in composition of pharmaceutical composition and in sets for screening of adhesion inhibitors of platelet adhesion or aggregation, is obtained in recombinant way applying matrix of cDNA of Anopheles stephensi salivary gland.

EFFECT: invention makes it possible to obtain polypeptide which possesses inhibiting activity with respect to platelet aggregation or inhibiting activity with respect to platelet adhesion.

10 cl, 4 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: strain of hybridioma is obtained by immunization of mice of line BALB/c. Mice are immunised by conventional method by double with thirty day exposition subcutaneous introduction of inactivated spores of B. Anthracis strain "СТИ-1". On the third day after last buster-injection carried out is hybridisation of splenocytes of immune mice (1×108 cells) with cells of mouse myeloma P3-X63 Ag/8-653 (1×107 cells), using for fusion polyethylene glycol (Sigma, USA). After hybridisation carried out are selection, screening, cloning and cryopreservation of hybridoma. Obtained hybridoma is deposited in collection of microorganisms of FSSE SRC AMB under number H10. Invention relates to biotechnology and can be used for obtaining monoclonal antibodies (MCA) to spores Bacillus anthracis. Strain productivity is 20-50 mcg/ml of monoclonal antibodies (MCAla in ascitic liquid- 5-10 mg/ml. Hybridoma produces MCA, related to IgGl subclass of mouse immunoglobulins and spores specific to Bac.anthracis.

EFFECT: increase of strain productivity.

7 dwg, 2 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention discloses peptides for detecting Mycobacterium tuberculosis, which consist of less than 18 amino acids and are capable of binding with the antibody against GRDIKVQFQSGGNNSPAV peptide (all sequences are given in a list of sequences). One of the peptides contains an NSPAX sequence, where X denotes methionine. More preferably, the peptides contain an NNSPAV sequence or have the type SGGNNSPAX, where X denotes methionine, leucine, alanine or valine. The invention describes a nucleotide sequence which codes the disclosed peptides, as well as an antibody or fragment thereof, capable of binding with said peptide. The invention discloses methods of detecting M.tuberculosis, involving ELISA substitutive analysis of a sample using a peptide capable of binding with the antibody against GRDIKVQFQSGGNNSPAV peptide or using the antidody.

EFFECT: use of the invention simplifies tests to determine anti-tuberculosis antibodies in a population owing to the artificially modified peptide sequences of T-cell epitope Ag85B M tuberculosis.

27 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: there are described polypeptides eliciting an immune response on H.influenzae. There is offered an antibody selectively binding specified polypeptides. The invention also concerns an immunogenic composition containing the described polypeptides.

EFFECT: invention can be used in medicine for treating or preventing a disease or an infection caused by Hinfluenzae, such as otitis media.

9 cl, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to biotechnology. Immunogenic composition is described comprising an effective amount of a combination of at least two different proteins or their immunogenic fragments selected from at least two groups of proteins or immunogenic fragments selected from the following groups: group (a): at least one staphylococcal protein binding an extracellular component, or its immunogenic fragment; group (b): at least one staphylococcal transport protein or its immunogenic fragment; group (c): at least one staphylococcal regulator of virulence, toxin or its immunogenic fragment, wherein at least one protein or an immunogenic fragment is selected from the group (a), and at least one protein or immunogenic fragment is selected from the group (b). A vaccine against staphylococcal infection is proposed, which comprises an effective amount of the immunogenic composition described. Also the method to obtain the vaccine is offered.

EFFECT: method for preventing or treating staphylococcal infection is proposed, comprising the introduction of the proposed vaccine, as well as method of producing immunoglobulin, comprising the steps of immunisation of the recipient by the proposed vaccine.

17 cl, 7 dwg, 8 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: there is produced a new CT-F5/H3 hybrid cell clone producing monoclonal cholera toxin antibody (MCAB) in the environment of cell culture and abdominal cavity of syngeneic animals. The clone is produced by the fusion of mouse myeloma SP-2/0 cells with popliteal lymph node cells of BALB/c mice immunised with a commercial preparation of cholera toxin (SIGMA) in posterior pads. A fusing agent is polyethylene glycol of molecular weight 4000. Hybridoma selection has been performed on Dulbecco modified Eagle's medium with bovine foetal serum and hypoxantine-aminopterin-thymidine added. Hybridoma synthesises MCAB specifically interacting with cholera toxin and not interacting with thermolabile E.coli toxin. The antibody titre reaches 1:20000 1:40000 in the cultural fluid, 1:4000000 in ascitic.

EFFECT: antibodies can be used for designing immunobiological systems of cholera toxin detection exceeding available analogues in sensitivity.

2 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: there is produced a new CT-E6/E10 hybrid cell clone producing monoclonal cholera toxin antibody in the environment of cell culture and abdominal cavity of syngeneic animals. The clone is produced by the fusion of mouse myeloma SP-2/0 cells with popliteal lymph node cells of BALB/c mice immunised with a commercial preparation of cholera toxin (SIGMA) in posterior pads. A fusing agent is polyethylene glycol of molecular weight 4000. Hybridoma selection has been performed on Dulbecco modified Eagle's medium with bovine foetal serum and hypoxantine-aminopterin-thymidine added. Hybridoma synthesises monoclonal antibodies specifically interacting with cholera toxin and not interacting with thermolabile E.coli toxin. The antibody titre reaches 1:10000 in the cultural fluid, 1:1000000 in ascitic.

EFFECT: produced antibodies exceeds the analogues available in sensitivity.

2 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: essence of invention includes contact of liquid sample, taken from mammal organism, with one or several monoclonal antibodies to Lawsonia intracellularis antigen, secreted by cell lines of ECACC hybridomes, which have registration numbers. Invention also includes diagnostic test-kit, containing antibodies specific for Lawsonia intracellularis.

EFFECT: increased specificity of antigen detection.

11 cl, 5 ex, 5 dwg

FIELD: medicine.

SUBSTANCE: method facilitates linkage of sequences, coding immunoglobulin variable regions, T-cells receptors or B-cells receptors. Method is instrument of higher effectivity for making sequence data libraries. Capability of multiple RT-PCR with chain extension by interruption with employment of matrix, derived from single cell, provides highly effective creation of sister pairs libraries.

EFFECT: method is effective for linkage of two or few nucleotide sequences, coding domens or subunits of heteromeric protein as a result of single reaction performance.

51 cl, 25 dwg, 27 tbl, 14 ex

FIELD: pharmacology.

SUBSTANCE: invention concerns biotechnology. There is described application of antibody to acetyl-CoA-acetyltransferase or its antigen-binding fragment in manufacturing of a medical product for treatment or prevention of the infection caused by Clostridium difficile and Enterococcus faecalis, faecium is described. There is disclosed combined preparation for treatment of the infection caused by Clostridium difficile containing (i) antibody to acetyl-CoA-acetyltransferase or its antigen-binding fragment; and (ii) at least one antibiotic from the group consisting of gentamycin, vancomycin and metronidazole. There is presented inhibitor of acetyl-CoA-acetyltransferase representing antibody or its antigen-binding fragment, containing at least one component of the group consisting of (i) complementarity determining regions (CDR) of 1-3 VH-chain; and (ii) complementarity determining regions (CDR) of 3 VL-chain. There is described method of treating the infection caused by Clostridium difficile, including introduction of therapeutically effective amount of antibody to acetyl-CoA-acetyltransferase to the medically indigent patient.

EFFECT: invention allows for prevention and treatment of the infection caused by bacteria Clostridium difficile and Enterococcus faecalis, faecium.

43 cl, 6 tbl

FIELD: medicine.

SUBSTANCE: method of preparing diagnostic agglutinating serum for pathogenic Yersinia strains involves hyperimmunisation of rabbits with antigen representing 0.4-0.6% formalin inactivated antigen (pYV+) of Yersinia enterocolitica My 03R strain into auricular cranial vein. Immunisation of rabbits with said antigen is fourfold in dosage as follows: 290-310 million kl/ml, 490-510 million kl/ml, 0.99-1.1 billion kl/ml and 1.9-2.1 billion kl/ml, respectively with dosage interval 6-7 days. Further the producer is examined for immunogenic properties. Serum separated from the sampled blood is preserved.

EFFECT: method ensures preparation of high-quality agglutinating serum used in yersiniosis diagnostics in animals.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns development of a diagnostic test system in immunochip format and a method of simultaneous and differential detection of reaginic antibodies and antibody spectrum to diagnostically significant mmunologically relevant proteins Treponema pallidum of G (IgG) and M (IgM) classes. The diagnostic test system in immunochip format for differential serum diagnostics of syphilis consists of an immunosorbent with separately immobilised antigens Treponema pallidum Tp15, Tp17, TmpA, Tp47, conjugate and reactants required to detect an antigen-antibody complex. Cardiolipin is additionally immobilised on the immunosorbent; antigens Treponema pallidum and cardiolipin are immobilised at least, in two repetitions, and conjugate consists of mixed antispecies human IgG antibodies and human IgM antibodies modified by two phosphors with different spectral characteristics. On the immunosorbent, there can be additionally immobilised at least, one antigen and/or peptide Treponema pallidum specified e.g. of Tp39, Tp41, Tp42, Tp44.5, Tp92, Tp0453 at least in two repetitions. Cardiolipin can represent an oxidised cardiolipin derivative bounded with protein. The differential serum syphilis diagnostic technique with using the diagnostic test system in immunochip format involves application of human IgM modified by two phosphors with different spectral characteristics. On the immunosorbent, there can be additionally immobilised at least one antigen and/or peptide Treponema pallidum, specified e.g. of Tp39, Tp41, Tp42, Tp44.5, Tp92, Tp0453 at least in two repetitions. Cardiolipin can represent an oxidised cardiolipin derivative bounded with protein. The differential serum syphilis diagnostic technique with using the diagnostic test system in immunochip format implying that a cultivation solution for check and test samples is introduced on the immunosorbent with separately immobilised antigens Treponema pallidum and cardiolipin; the check and test samples are introduced; the prepared mixture is incubated at temperature 20-42°C for 15-60 min to prepare the antigen-antibody complex; the immunosorbent is rinsed; then a conjugate solution of mixed human IgG antibodies and human IgM antibodies modified by two phosphors with different spectral characteristics is introduced on the immunosorbent; it is followed with incubation at temperature 20-42°C for 15-60 min; the immunosorbent is rinsed, dried to detect the prepared antigen-antibody complex.

EFFECT: improved diagnostic accuracy.

20 cl, 5 dwg, 2 ex

Up!